Clonal deleterious mutations in the IkappaBalpha gene in the malignant cells in Hodgkin's lymphoma

J Exp Med. 2000 Jan 17;191(2):395-402. doi: 10.1084/jem.191.2.395.

Abstract

Members of the nuclear factor (NF)-kappaB family of transcription factors play a crucial role in cellular activation, immune responses, and oncogenesis. In most cells, they are kept inactive in the cytosol by complex formation with members of the inhibitor of NF-kappaB (IkappaB) family, whose degradation activates NF-kappaB in response to diverse stimuli. In Hodgkin's lymphoma (HL), high constitutive nuclear activity of NF-kappaB is characteristic of the malignant Hodgkin and Reed-Sternberg (H/RS) cells, which occur at low number in a background of nonneoplastic inflammatory cells. In single H/RS cells micromanipulated from histological sections of HL, we detect clonal deleterious somatic mutations in the IkappaBalpha gene in two of three Epstein-Barr virus (EBV)-negative cases but not in two EBV-positive cases (in which a viral oncogene may account for NF-kappaB activation). There was no evidence for IkappaBalpha mutations in two non-HL entities or in normal germinal center B cells. This study establishes deleterious IkappaBalpha mutations as the first recurrent genetic defect found in H/RS cells, indicating a role of IkappaBalpha defects in the pathogenesis of HL and implying that IkappaBalpha is a tumor suppressor gene.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Child
  • DNA-Binding Proteins / genetics*
  • Female
  • Gene Deletion*
  • Hodgkin Disease / genetics*
  • Humans
  • I-kappa B Proteins*
  • Male
  • NF-KappaB Inhibitor alpha
  • Tumor Cells, Cultured

Substances

  • DNA-Binding Proteins
  • I-kappa B Proteins
  • NFKBIA protein, human
  • NF-KappaB Inhibitor alpha